Your browser doesn't support javascript.
loading
Comparison of Recommendations Made by Committee Members with and without Financial Conflict of Interest on Japanese Guideline of Treatment of Hyperuricemia and Gout, Third Edition.
Hisatome, Ichiro; Hamada, Toshihiro; Mizuta, Einosuke; Ohtahara, Akira; Kuwabara, Masanari; Ogino, Kazuhide; Ninomiya, Haruaki; Sato, Yasuto; Nakayama, Takeo; Yamanaka, Hisashi.
Afiliación
  • Hisatome I; Department of Cardiology, National Hospital Organization, Yonago Medical Center, Yonago, Japan.
  • Hamada T; Department of Community-based Family Medicine, Tottori University Faculty of Medicine, Yonago, Japan.
  • Mizuta E; Department of Cardiology, Sanin Rosai Hospital, Yonago, Japan.
  • Ohtahara A; Department of Cardiology, Sanin Rosai Hospital, Yonago, Japan.
  • Kuwabara M; Department of Cardiology, Toranomon Hospital, Tokyo, Japan.
  • Ogino K; Department of Cardiology, Japanese Red Cross Tottori Hospital, Tottori, Japan.
  • Ninomiya H; Department of Biological Regulation, Tottori University Faculty of Medicine, Yonago, Japan.
  • Sato Y; Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan.
  • Nakayama T; Department of Health Informatics, Graduate School of Medicine & School of Public Health, Kyoto University, Kyoto, Japan.
  • Yamanaka H; Department of Rheumatology, Sanno Medical Center, Tokyo, Japan.
JMA J ; 6(4): 523-526, 2023 Oct 16.
Article en En | MEDLINE | ID: mdl-37941684
ABSTRACT
Clinical practice guidelines (CPGs) consist of clinical questions (CQs) and corresponding recommendations. Considering the estimation of body of evidence, patients' opinions, and medical economics, recommendations can vary depending on the votes of the committee members of CPGs. Taking this into consideration, concerns have already been raised on how financial conflict of interest (COI) potentially influences recommendations. In this study, we developed the third edition of guideline for the management of hyperuricemia and gout. This CPG was composed of seven CQs and recommendations. The direction and strength of the recommendations were determined by votes. There are three CQs. Individual questions asked whether uric acid-lowering-agents (ULAs) could be applied to hyperuricemic patients with chronic kidney disease (CKD) (CQ A), hypertension (CQ B), or heart failure (CQ C) to prevent organ damage. We examined whether the absence (18 members) or presence (8 members) of COIs of committee members could influence the votes. In total, 26 committee members with and without COI have equally determined the direction and strength of recommendations. In CQ A, members without financial COIs and those with financial COI selected conditional recommendation for the use of ULAs in patients with CKD (without COI, 17/18; with COI, 7/8). In CQ B, members without financial COIs and those with financial COI selected conditional recommendation against the use of ULAs in hypertensive patients (without COI, 14/18; with COI, 5/8). In CQ C, members without financial COIs and those with financial COIs have selected conditional recommendation against the use of ULAs in patients suffering from heart failure (without COI, 15/18; with COI, 4/8). We found that members with financial COIs have determined their recommendations in the same direction and strength as those without financial COIs.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JMA J Año: 2023 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JMA J Año: 2023 Tipo del documento: Article País de afiliación: Japón
...